Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9825748rdf:typepubmed:Citationlld:pubmed
pubmed-article:9825748lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:9825748lifeskim:mentionsumls-concept:C0024141lld:lifeskim
pubmed-article:9825748lifeskim:mentionsumls-concept:C0085278lld:lifeskim
pubmed-article:9825748lifeskim:mentionsumls-concept:C0162596lld:lifeskim
pubmed-article:9825748lifeskim:mentionsumls-concept:C0023981lld:lifeskim
pubmed-article:9825748pubmed:issue10lld:pubmed
pubmed-article:9825748pubmed:dateCreated1998-12-3lld:pubmed
pubmed-article:9825748pubmed:abstractTextTo determine anti-beta2 glycoprotein-I (anti-beta2GPI) and anti-prothrombin (anti-ProT) antibody levels, and the IgG subclass distribution of anti-beta2GPI antibodies, in serial samples from patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS) having initial or recurrent thrombotic/neurological (T/N) events during the study period. To investigate the correlations between these antibodies and beta2GPI antigen, anticardiolipin antibody (aCL), anti-double-stranded (ds) DNA, C3 levels and disease activity.lld:pubmed
pubmed-article:9825748pubmed:languageenglld:pubmed
pubmed-article:9825748pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825748pubmed:citationSubsetAIMlld:pubmed
pubmed-article:9825748pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825748pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825748pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825748pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825748pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825748pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825748pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825748pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9825748pubmed:statusMEDLINElld:pubmed
pubmed-article:9825748pubmed:monthOctlld:pubmed
pubmed-article:9825748pubmed:issn0263-7103lld:pubmed
pubmed-article:9825748pubmed:authorpubmed-author:MackieIIlld:pubmed
pubmed-article:9825748pubmed:authorpubmed-author:IsenbergD ADAlld:pubmed
pubmed-article:9825748pubmed:authorpubmed-author:MachiiTTlld:pubmed
pubmed-article:9825748pubmed:authorpubmed-author:RavirajanC...lld:pubmed
pubmed-article:9825748pubmed:authorpubmed-author:InariKKlld:pubmed
pubmed-article:9825748pubmed:authorpubmed-author:Radway-Bright...lld:pubmed
pubmed-article:9825748pubmed:authorpubmed-author:DonohoeSSlld:pubmed
pubmed-article:9825748pubmed:issnTypePrintlld:pubmed
pubmed-article:9825748pubmed:volume37lld:pubmed
pubmed-article:9825748pubmed:ownerNLMlld:pubmed
pubmed-article:9825748pubmed:authorsCompleteYlld:pubmed
pubmed-article:9825748pubmed:pagination1089-94lld:pubmed
pubmed-article:9825748pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:meshHeadingpubmed-meshheading:9825748-...lld:pubmed
pubmed-article:9825748pubmed:year1998lld:pubmed
pubmed-article:9825748pubmed:articleTitleAnti-beta2-glycoprotein I, anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome.lld:pubmed
pubmed-article:9825748pubmed:affiliationDepartment of Medicine, University College London.lld:pubmed
pubmed-article:9825748pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9825748pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:9825748pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9825748lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9825748lld:pubmed